Cargando…

Correction to: Daridorexant in Insomnia Disorder: A Profile of Its Use

Detalles Bibliográficos
Autores principales:	Nie, Tina, Blair, Hannah A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer International Publishing 2023
Materias:	Correction
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10024654/ https://www.ncbi.nlm.nih.gov/pubmed/36826776 http://dx.doi.org/10.1007/s40263-023-00994-w

Ejemplares similares

Daridorexant in Insomnia Disorder: A Profile of Its Use
por: Nie, Tina, et al.
Publicado: (2023)

Correction to: Daridorexant: First Approval
por: Markham, Anthony
Publicado: (2022)

Long-Term Safety and Tolerability of Daridorexant in Patients with Insomnia Disorder
por: Kunz, Dieter, et al.
Publicado: (2022)

Number, Duration, and Distribution of Wake Bouts in Patients with Insomnia Disorder: Effect of Daridorexant and Zolpidem
por: Di Marco, Tobias, et al.
Publicado: (2023)

Use of Daridorexant among Patients with Chronic Insomnia: A Retrospective Observational Analysis
por: Williams, Scott G., et al.
Publicado: (2023)

Daridorexant for the treatment of insomnia disorder: A systematic review and meta-analysis of randomized controlled trials
por: Jiang, Feiyu, et al.
Publicado: (2023)

Nonclinical pharmacology of daridorexant: a new dual orexin receptor antagonist for the treatment of insomnia
por: Roch, Catherine, et al.
Publicado: (2021)

Daridorexant: First Approval
por: Markham, Anthony
Publicado: (2022)

Daridorexant, a Recently Approved Dual Orexin Receptor Antagonists (DORA) in Treatment of Insomnia
por: Sarathi Chakraborty, Dwaipayan, et al.
Publicado: (2023)

Correction to: Inebilizumab: A Review in Neuromyelitis Optica Spectrum Disorder
por: Nie, Tina, et al.
Publicado: (2022)

Efficacy and Safety of Daridorexant in Older and Younger Adults with Insomnia Disorder: A Secondary Analysis of a Randomised Placebo-Controlled Trial
por: Fietze, Ingo, et al.
Publicado: (2022)

A Comprehensive Review of Daridorexant, a Dual-Orexin Receptor Antagonist as New Approach for the Treatment of Insomnia
por: Ziemichód, Wojciech, et al.
Publicado: (2022)

Meaningful Within-Patient Change on the Insomnia Daytime Symptoms and Impacts Questionnaire (IDSIQ): Analysis of Phase III Clinical Trial Data of Daridorexant
por: Phillips-Beyer, Andrea, et al.
Publicado: (2023)

Management of insomnia in primary care [Correction]
Publicado: (2021)

Pharmacokinetics of daridorexant, a dual orexin receptor antagonist, are not affected by renal impairment
por: Berger, Benjamin, et al.
Publicado: (2021)

Driving Performance after Bedtime Administration of Daridorexant, Assessed in a Sensitive Simulator
por: Muehlan, Clemens, et al.
Publicado: (2022)

Population pharmacokinetic modeling of daridorexant, a novel dual orexin receptor antagonist
por: Krause, Andreas, et al.
Publicado: (2022)

Correction to: Calcium, Magnesium, Potassium and Sodium Oxybates (Xywav(®)) in Sleep Disorders: A Profile of Its Use
por: Heo, Young-A
Publicado: (2022)

Correction: Effects of E-aid cognitive behavioral therapy for insomnia (eCBTI) to prevent the transition from episodic insomnia to persistent insomnia: study protocol for a randomized controlled trial
Publicado: (2020)

Correction to: Swedish translation and validation of the Pediatric Insomnia Severity Index
por: Angelhoff, Charlotte, et al.
Publicado: (2020)

Correction to: Anakinra in Still’s disease: a profile of its use
por: Lyseng‑Williamson, Katherine A.
Publicado: (2018)

Correction to: Afatinib in advanced NSCLC: a profile of its use
por: Deeks, Emma D., et al.
Publicado: (2018)

Correction to: Filgotinib in Rheumatoid Arthritis: A Profile of Its Use
por: Kim, Esther S., et al.
Publicado: (2021)

Correction to: Remdesivir: A Review in COVID-19
por: Blair, Hannah A.
Publicado: (2023)

Correction to: Secukinumab: A Review in Ankylosing Spondylitis
por: Blair, Hannah A.
Publicado: (2019)

Correction to: Tiotropium/Olodaterol: A Review in COPD
por: Blair, Hannah A.
Publicado: (2019)

Correction to: Secukinumab: A Review in Psoriatic Arthritis
por: Blair, Hannah A.
Publicado: (2021)

Correction to: Ritlecitinib: First Approval
por: Blair, Hannah A.
Publicado: (2023)

Correction to: Sotorasib: First Approval
por: Blair, Hannah A.
Publicado: (2021)

Correction to: Belumosudil: First Approval
por: Blair, Hannah A.
Publicado: (2021)

Correction to: Spesolimab: First Approval
por: Blair, Hannah A.
Publicado: (2022)

Correction: Acupuncture for insomnia with short sleep duration: protocol for a randomised controlled trial
Publicado: (2020)

Correction to: Behavior-analytic intervention for women with fibromyalgia and insomnia: a single subject design
por: de Fátima Kirchner, Luziane, et al.
Publicado: (2021)

Correction to: OnabotulinumtoxinA in Chronic Migraine: A Profile of Its Use
por: Frampton, James E.
Publicado: (2021)

Correction to: Risankizumab: A Review in Moderate to Severe Plaque Psoriasis
por: Blair, Hannah A.
Publicado: (2020)

Correction to: Efgartigimod Alfa in Generalised Myasthenia Gravis: A Profile of Its Use
por: Heo, Young-A
Publicado: (2023)

Correction to: Burosumab in X-linked hypophosphatemia: a profile of its use in the USA
por: Lyseng-Williamson, Katherine A.
Publicado: (2018)

Correction to: Perindopril/Indapamide/Amlodipine in Hypertension: A Profile of Its Use
por: Syed, Yahiya Y.
Publicado: (2022)

Correction to: Fostamatinib in chronic immune thrombocytopenia: a profile of its use in the USA
por: McKeage, Kate, et al.
Publicado: (2018)

Correction to: Rimegepant: A Review in the Acute Treatment and Preventive Treatment of Migraine
por: Blair, Hannah A.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_703npjjdbih4chobl0n59bipg0